Edition:
India

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

77.57USD
18 Apr 2019
Change (% chg)

$-0.41 (-0.53%)
Prev Close
$77.98
Open
$78.01
Day's High
$78.21
Day's Low
$76.82
Volume
1,941,417
Avg. Vol
1,748,081
52-wk High
$107.24
52-wk Low
$75.77

Latest Key Developments (Source: Significant Developments)

British Columbia Pharmacare Lists Abbvie's Hepatitis C Treatment Maviret On Its Formulary
Friday, 22 Mar 2019 

March 22 (Reuters) - AbbVie Inc ::BRITISH COLUMBIA PHARMACARE LISTS ABBVIE'S HEPATITIS C TREATMENT MAVIRET™ ON ITS FORMULARY.ABBVIE INC - BRITISH COLUMBIA PHARMACARE LISTS MAVIRET ON ITS FORMULARY EFFECTIVE MARCH 21, 2019.  Full Article

FDA Warns About Risks Associated With Investigational Use Of Venclexta In Multiple Myeloma
Friday, 22 Mar 2019 

March 21 (Reuters) - U.S. Food and Drug Administration::FDA WARNS ABOUT THE RISKS ASSOCIATED WITH THE INVESTIGATIONAL USE OF VENCLEXTA IN MULTIPLE MYELOMA.FDA - REVIEWED DATA FROM THE BELLINI CLINICAL TRIAL EVALUATING USE OF VENCLEXTA COMBINED WITH BORTEZOMIB & DEXAMETHASONE IN MULTIPLE MYELOMA PATIENTS.FDA - INTERIM TRIAL RESULTS FROM BELLINI CLINICAL TRIAL DEMONSTRATED INCREASED RISK OF DEATH FOR PATIENTS RECEIVING VENCLEXTA VERSUS THE CONTROL GROUP.FDA - PATIENTS TAKING VENCLEXTA FOR AN APPROVED INDICATION SHOULD CONTINUE TO TAKE THEIR MEDICATION AS DIRECTED BY THEIR HEALTH CARE PROFESSIONAL.  Full Article

AbbVie Announces Multiple Milestones for Phase 3 CLL14 Venetoclax Study of Fixed Duration Treatment
Thursday, 7 Mar 2019 

March 7 (Reuters) - AbbVie Inc ::ABBVIE ANNOUNCES MULTIPLE MILESTONES FOR PHASE 3 CLL14 VENETOCLAX STUDY OF FIXED DURATION TREATMENT IN PREVIOUSLY-UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS.ABBVIE INC - FDA HAS ALSO GRANTED VENETOCLAX A FIFTH BREAKTHROUGH THERAPY DESIGNATION (BTD) BASED ON PHASE 3 CLL14 CLINICAL TRIAL.ABBVIE INC - FDA WILL REVIEW APPLICATION UNDER REAL-TIME ONCOLOGY REVIEW (RTOR) PILOT PROGRAM, SIGNALING AGENCY'S INTENTION TO EXPEDITE REVIEW.  Full Article

Voyager Therapeutics And Abbvie Announce Collaboration
Friday, 22 Feb 2019 

Feb 22 (Reuters) - AbbVie Inc ::VOYAGER THERAPEUTICS AND ABBVIE ANNOUNCE COLLABORATION TO DEVELOP VECTORIZED ANTIBODIES TO TREAT PARKINSON’S DISEASE AND OTHER SYNUCLEINOPATHIES.VOYAGER THERAPEUTICS INC - VOYAGER TO RECEIVE $65 MILLION UPFRONT.VOYAGER THERAPEUTICS INC - TO RECEIVE UP TO $245 MILLION IN PRECLINICAL, PHASE 1 OPTION PAYMENTS, POTENTIAL DEVELOPMENT, OTHERS.VOYAGER THERAPEUTICS INC - VOYAGER IS ALSO ELIGIBLE TO RECEIVE UP TO AN ADDITIONAL $728 MILLION IN POTENTIAL DEVELOPMENT AND REGULATORY MILESTONE PAYMENTS.VOYAGER THERAPEUTICS - ELIGIBLE TO RECEIVE TIERED ROYALTIES ON GLOBAL COMMERCIAL NET SALES OF EACH ALPHA-SYNUCLEIN VECTORIZED ANTIBODY.VOYAGER THERAPEUTICS INC - VOYAGER WILL BE RESPONSIBLE FOR RESEARCH, IND-ENABLING AND PHASE 1 CLINICAL ACTIVITIES AND COSTS..VOYAGER THERAPEUTICS - MAY ALSO EARN UP TO A TOTAL OF $500 MILLION IN COMMERCIAL MILESTONES..VOYAGER - ABBVIE HAS OPTION TO LICENSE VECTORIZED ALPHA-SYNUCLEIN ANTIBODY PROGRAM FOR FURTHER CLINICAL DEVELOPMENT AND GLOBAL COMMERCIALIZATION.  Full Article

Abbvie And Teneobio Announce A Strategic Transaction To Develop New Treatment For Multiple Myeloma
Monday, 11 Feb 2019 

Feb 11 (Reuters) - AbbVie Inc ::ABBVIE AND TENEOBIO ANNOUNCE A STRATEGIC TRANSACTION TO DEVELOP A NEW TREATMENT FOR MULTIPLE MYELOMA.ABBVIE INC - TENEOONE WILL RECEIVE AN UPFRONT PAYMENT OF $90 MILLION.ABBVIE INC - TENEOBIO IS EXPECTED TO BEGIN CLINICAL PROGRAM FOR TNB-383B IN FIRST HALF OF 2019..ABBVIE INC - TENEOONE WILL CONTINUE DEVELOPING TNB-383B THROUGH PHASE 1.ABBVIE INC - ABBVIE WILL HOLD EXCLUSIVE RIGHT TO ACQUIRE TENEOONE AND LEAD SUBSEQUENT GLOBAL DEVELOPMENT AND COMMERCIALIZATION OF TNB-383B.  Full Article

Abbvie Says Non-Humira Sales To Grow To More Than $35 Bln In 2025
Wednesday, 9 Jan 2019 

Jan 9 (Reuters) - AbbVie Inc ::ABBVIE INC SAYS NON-HUMIRA SALES TO GROW TO MORE THAN $35 BILLION IN 2025- JP MORGAN CONF.ABBVIE INC SAYS MAVYRET WILL REMAIN A STRONG SOURCE OF CASH FLOW OVER LONG RANGE PLAN PERIOD - JP MORGAN CONF.ABBVIE INC EXPECTS ELAGOLIX FOR ENDOMETRIOSIS AND UTERINE FIBROIDS TO BRING IN OVER $2 BILLION IN SALES BY 2025 - JP MORGAN CONF.ABBVIE INC EXPECTS HEMATOLOGIC ONCOLOGY FRANCHISE TO BRING IN OVER $9 BILLION IN SALES BY 2025 - JP MORGAN CONF.ABBVIE INC EXPECTS IMMUNOLOGY DRUGS UPADACITINIB AND RISANKIZUMAB TO BRING IN OVER $10 BILLION IN SALES BY 2025 - JP MORGAN CONF.ABBVIE PRESIDENT MICHAEL SEVERINO SAYS CO EXPECTS TO DRIVE STRONG GROWTH IN 2019 EVEN AS IT FACES DIRECT BIOSIMILAR COMPETITION ACROSS MAJORITY OF INTERNATIONAL MARKETS - JP MORGAN CONF.ABBVIE INC EXPECTS HUMIRA TO REMAIN MARKET LEADER THROUGH 2022 - JP MORGAN CONF.ABBVIE INC EXPECTS ONCOLOGY TO BE MAJOR GROWTH DRIVER OVER NEXT DECADE AND BEYOND- JP MORGAN CONF.ABBVIE INC EXPECTS HCV WILL BE A DURABLE MARKET INTO THE 2020'S - JP MORGAN CONF.ABBVIE PRESIDENT MICHAEL SEVERINO SAYS "WE WILL CONTINUE TO AUGMENT OUR PIPELINE THROUGH STRATEGIC LICENSING, ACQUISITIONS AND PARTNERING" - JP MORGAN CONF.ABBVIE PRESIDENT MICHAEL SEVERINO SAYS CO IS "ALWAYS LOOKING" TO GROW BUSINESS, IS COMMITTED TO GROWING DIVIDEND AND WILL BUY BACK SHARES OPPORTUNISTICALLY - JP MORGAN CONF.  Full Article

Abbvie Announces Executive Leadership Changes
Monday, 17 Dec 2018 

Dec 17 (Reuters) - AbbVie Inc ::ABBVIE ANNOUNCES EXECUTIVE LEADERSHIP CHANGES.ABBVIE INC - MICHAEL E. SEVERINO CO'S EVP , RESEARCH & DEVELOPMENT & CHIEF SCIENTIFIC OFFICER, HAS BEEN NAMED VICE CHAIRMAN AND PRESIDENT.ABBVIE INC - LAURA J. SCHUMACHER HAS BEEN NAMED VICE CHAIRMAN, EXTERNAL AFFAIRS AND CHIEF LEGAL OFFICER.ABBVIE INC - CARLOS ALBAN, WHO CURRENTLY SERVES AS EVP, COMMERCIAL OPERATIONS, HAS BEEN NAMED VICE CHAIRMAN, CHIEF COMMERCIAL OFFICER.  Full Article

Abbvie Announces $5 Bln Increase To Stock Repurchase Program
Thursday, 13 Dec 2018 

Dec 13 (Reuters) - AbbVie Inc ::ABBVIE ANNOUNCES $5 BILLION INCREASE TO STOCK REPURCHASE PROGRAM.  Full Article

AbbVie Inc - Phase 3 Trial Of Rova-T As Second-Line Therapy For Advanced Small-Cell Lung Cancer Halted
Thursday, 6 Dec 2018 

Dec 5 (Reuters) - AbbVie Inc ::PHASE 3 TRIAL OF ROVA-T AS SECOND-LINE THERAPY FOR ADVANCED SMALL-CELL LUNG CANCER (TAHOE STUDY) HALTED.INDEPENDENT DATA MONITORING COMMITTEE RESPONSIBLE FOR ONGOING REVIEW OF STUDY DATA RECOMMENDED ENROLLMENT BE STOPPED.INDEPENDENT DATA MONITORING COMMITTEE RESPONSIBLE FOR ONGOING REVIEW OF STUDY DATA RECOMMENDED ENROLLMENT BE STOPPED.RECOMMENDATION FROM IDMC TO HALT ENROLLMENT APPLIES ONLY TO TAHOE STUDY AND DOES NOT IMPACT OTHER ROVA-T CLINICAL STUDIES.AN IDMC RECOMMENDED STOPPING ENROLLMENT IN TAHOE DUE TO SHORTER OVERALL SURVIVAL IN ROVA-T ARM COMPARED WITH TOPOTECAN CONTROL ARM.  Full Article

Genentech Says FDA Approves Venclexta in Newly-Diagnosed AML
Wednesday, 21 Nov 2018 

Nov 21 (Reuters) - Genentech::GENENTECH - FDA GRANTED ACCELERATED APPROVAL TO VENCLEXTA, IN COMBINATION WITH A HYPOMETHYLATING AGENT, OR LOW-DOSE CYTARABINE IN NEWLY-DIAGNOSED AML.  Full Article

Photo

FDA puts partial hold on clinical trials of AbbVie's cancer drug

AbbVie Inc said on Tuesday the U.S. Food and Drug Administration placed a partial clinical hold on all trials of its cancer drug Venclexta for multiple myeloma, after a review of data found a higher proportion of deaths in the Venclexta arm of the late-stage study.